Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Bought by Commonwealth Equity Services Inc

Commonwealth Equity Services Inc increased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 33,552 shares of the medical equipment provider’s stock after buying an additional 914 shares during the period. Commonwealth Equity Services Inc’s holdings in Zimmer Biomet were worth $3,928,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. JPMorgan Chase & Co. lifted its stake in shares of Zimmer Biomet by 92.7% in the second quarter. JPMorgan Chase & Co. now owns 3,279,951 shares of the medical equipment provider’s stock worth $421,146,000 after buying an additional 1,577,874 shares in the last quarter. Harbour Capital Advisors LLC increased its position in Zimmer Biomet by 13,131.3% during the second quarter. Harbour Capital Advisors LLC now owns 1,302,618 shares of the medical equipment provider’s stock worth $10,145,000 after purchasing an additional 1,292,773 shares during the last quarter. Longview Partners Guernsey LTD increased its position in Zimmer Biomet by 17.7% during the third quarter. Longview Partners Guernsey LTD now owns 7,506,684 shares of the medical equipment provider’s stock worth $878,958,000 after purchasing an additional 1,128,973 shares during the last quarter. Koch Industries Inc. increased its position in Zimmer Biomet by 49,697.3% during the second quarter. Koch Industries Inc. now owns 1,040,764 shares of the medical equipment provider’s stock worth $1,033,000 after purchasing an additional 1,038,674 shares during the last quarter. Finally, BlackRock Inc. increased its position in Zimmer Biomet by 4.1% during the second quarter. BlackRock Inc. now owns 17,419,463 shares of the medical equipment provider’s stock worth $2,236,657,000 after purchasing an additional 679,080 shares during the last quarter. 86.24% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Zimmer Biomet Holdings, Inc. (NYSE ZBH) traded up $0.29 on Wednesday, reaching $115.78. 917,133 shares of the company’s stock traded hands, compared to its average volume of 1,356,597. The company has a quick ratio of 0.78, a current ratio of 1.47 and a debt-to-equity ratio of 0.88. Zimmer Biomet Holdings, Inc. has a 12 month low of $100.81 and a 12 month high of $133.49. The firm has a market cap of $23,247.96, a PE ratio of 14.23, a P/E/G ratio of 1.78 and a beta of 1.15.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02). Zimmer Biomet had a return on equity of 16.29% and a net margin of 8.36%. The company had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.83 billion. During the same period last year, the company earned $1.79 earnings per share. The business’s revenue for the quarter was down .8% compared to the same quarter last year. sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.03 EPS for the current fiscal year.

A number of equities research analysts have weighed in on the stock. Stifel Nicolaus reiterated a “hold” rating and set a $120.00 price target on shares of Zimmer Biomet in a research report on Friday, November 3rd. TheStreet cut shares of Zimmer Biomet from a “b-” rating to a “c+” rating in a research report on Friday, November 24th. SunTrust Banks set a $136.00 price objective on shares of Zimmer Biomet and gave the company a “buy” rating in a research note on Wednesday, November 1st. Piper Jaffray Companies downgraded shares of Zimmer Biomet from an “overweight” rating to a “neutral” rating in a research note on Thursday, November 2nd. Finally, Gabelli started coverage on shares of Zimmer Biomet in a research note on Thursday, August 24th. They issued a “buy” rating and a $142.00 price target for the company. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Zimmer Biomet has an average rating of “Hold” and a consensus target price of $133.71.

TRADEMARK VIOLATION WARNING: “Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Bought by Commonwealth Equity Services Inc” was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://ledgergazette.com/2017/12/07/zimmer-biomet-holdings-inc-zbh-shares-bought-by-commonwealth-equity-services-inc.html.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply